OneSource Specialty Pharma has announced impressive financial results for the third quarter of FY25, marking a strong beginning as an independent company following its recent listing.

The company reported consolidated revenues of INR 3,926 million for Q3FY25, reflecting an 18 percent quarter-on-quarter growth.

OneSource demonstrated exceptional profitability with EBITDA reaching INR 1,432 million, an 85 percent increase compared to the previous quarter, resulting in a robust EBITDA margin of 36.5 percent, up by 1,334 basis points quarter-on-quarter.

The company’s normalized Profit After Tax (PAT) stood at INR 898 million, translating to an Earnings Per Share (EPS) of INR 7.8 for the quarter. However, the reported PAT was affected by one-time costs associated with the company's setup and transaction-related expenses.

Gross margin for Q3FY25 surged to INR 3,023 million from INR 2,240 million in Q2FY25, representing a 35 percent quarter-on-quarter increase. The gross margin percentage improved significantly to 77 percent, up by 995 basis points compared to the previous quarter. Over the nine-month period of FY25, the company reported total revenues of INR 10,189 million and an EBITDA of INR 2,848 million, maintaining a strong financial trajectory.

Neeraj Sharma, CEO, OneSource Specialty Pharma Limited speaking on the performance said, “We're off to a promising start as an independent platform. Our strong Q3 results and impressive new business wins across various modalities demonstrate we're on the path to continued growth and profitability while achieving the targeted FY25 outcomes. We're committed to providing significant value and establishing ourselves as the leading Indian CDMO on a global stage.”

OneSource Specialty Pharma Limited, formerly known as Stelis Biopharma Limited, is India's first specialty pharma pure-play Contract Development and Manufacturing Organization (CDMO). The company offers comprehensive solutions across various platforms and therapeutic modalities, including drug-device combinations, biologics, sterile injectables, and oral technologies.

Operating with five state-of-the-art facilities approved by major regulatory authorities such as the USFDA and EU authorities, OneSource continues to support its global partners in delivering life-saving pharmaceutical solutions.